← Leaderboards
Vera P Krymskaya
University Of Pennsylvania
$16,207,847
Attributed
$17,608,384
Total exposure
12
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,608,384 · 12
By mechanism
R01$16,720,971 · 8
R41$857,413 · 3
R13$30,000 · 1
Top collaborators
- Victoria Stepanova4 shared
- Dirk Pleimes3 shared
- Jacob Brenner1 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Alexander E. Perl$861,840
- Bridget Gosis$115,370
- Chelsea Thorsheim$140,028
- Victoria Stepanova$1,307,539
- Abeed H Sarker$3,682,140
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungLymphangioleiomyomatosisCellsInsightSirolimusLung DiseasesSignal TransductionTuberous Sclerosis Protein ComplexPulmonary FunctionTsc2 GeneTherapeutic TargetMutationIn VivoLesionAffectGrowthTumorWomanPathway InteractionsGeneticFrap1 GeneCell GrowthLung LymphangioleiomyomatosisCyst
Grant awards (40)
The 2025 LAM Foundation International Lymphangioleiomyomatosis Research Conference$30,000
R13 · FY2025 · HL · contact PI
mTORC1 and WNT in lung mesenchyme$604,152
R01 · FY2024 · HL · contact PI
mTORC1 and WNT in lung mesenchyme$616,480
R01 · FY2023 · HL · contact PI
mTOR signaling in lung homeostasis, aging and disease$488,290
R01 · FY2023 · HL · contact PI
miRNA-Nanotechnology as a novel regenerative therapy for lymphangioleiomyomatosis$301,016
R41 · FY2023 · HG
Novel Combination Therapy for Treatment and Prevention of PulmonaryLymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Complex (TSC)$299,997
R41 · FY2023 · HL
mTORC1 and WNT in lung mesenchyme$616,480
R01 · FY2022 · HL · contact PI
mTOR signaling in lung homeostasis, aging and disease$488,290
R01 · FY2022 · HL · contact PI
Urokinase-type plasminogen activator (uPA) in pathogenesis of lymphangioleiomyomatosis (LAM)$449,396
R01 · FY2022 · HL
mTORC1 and WNT in lung mesenchyme$656,053
R01 · FY2021 · HL · contact PI
mTOR signaling in lung homeostasis, aging and disease$488,040
R01 · FY2021 · HL · contact PI
Urokinase-type plasminogen activator (uPA) in pathogenesis of lymphangioleiomyomatosis (LAM)$460,081
R01 · FY2021 · HL
Nitazoxanide as a Novel Therapy for Rare Disease Lymphangioleiomyomatosis and Tuberous Sclerosis$256,400
R41 · FY2021 · HL
mTOR signaling in lung homeostasis, aging and disease$486,787
R01 · FY2020 · HL · contact PI
Urokinase-type plasminogen activator (uPA) in pathogenesis of lymphangioleiomyomatosis (LAM)$461,690
R01 · FY2020 · HL
Lymphangiogenesis in Pulmonary Lymphangioleiomyomatosis (LAM)$632,220
R01 · FY2019 · HL · contact PI
Urokinase-type plasminogen activator (uPA) in pathogenesis of lymphangioleiomyomatosis (LAM)$472,155
R01 · FY2019 · HL
Lymphangiogenesis in Pulmonary Lymphangioleiomyomatosis (LAM)$633,911
R01 · FY2018 · HL · contact PI
Lymphangiogenesis in Pulmonary Lymphangioleiomyomatosis (LAM)$635,396
R01 · FY2017 · HL · contact PI
Lymphangiogenesis in Pulmonary Lymphangioleiomyomatosis (LAM)$651,186
R01 · FY2016 · HL · contact PI
TSC signaling and pulmonary LAM$475,982
R01 · FY2015 · HL · contact PI
Role of folliculin (FLCN) in lung cell survival$449,181
R01 · FY2015 · HL · contact PI
TSC signaling and pulmonary LAM$473,565
R01 · FY2014 · HL · contact PI
Role of folliculin (FLCN) in lung cell survival$446,902
R01 · FY2014 · HL · contact PI
TSC signaling and pulmonary LAM$471,458
R01 · FY2013 · HL · contact PI
Role of folliculin (FLCN) in lung cell survival$434,133
R01 · FY2013 · HL · contact PI
Role of folliculin (FLCN) in lung cell survival$515,522
R01 · FY2012 · HL · contact PI
TSC signaling and pulmonary LAM$492,730
R01 · FY2012 · HL · contact PI
The Role of TSC2 and Rho GTPases in LAM$393,750
R01 · FY2011 · HL · contact PI
The Role of TSC2 and Rho GTPases in LAM$393,750
R01 · FY2010 · HL · contact PI
Role of p70 S6 Kinase in Regulating LAM Cell Growth$354,375
R01 · FY2010 · HL · contact PI
The Role of TSC2 and Rho GTPases in LAM$393,750
R01 · FY2009 · HL · contact PI
Role of p70 S6 Kinase in Regulating LAM Cell Growth$354,375
R01 · FY2009 · HL · contact PI
The Role of TSC2 and Rho GTPases in LAM$393,750
R01 · FY2008 · HL · contact PI
Role of p70 S6 Kinase in Regulating LAM Cell Growth$354,375
R01 · FY2008 · HL · contact PI
Role of p70 S6 Kinase in Regulating LAM Cell Growth$373,266
R01 · FY2007 · HL · contact PI
Role of p70 S6 Kinase in Regulating LAM Cell Growth$277,375
R01 · FY2005 · HL
Role of p70 S6 Kinase in Regulating LAM Cell Growth$277,375
R01 · FY2004 · HL
Role of p70 S6 Kinase in Regulating LAM Cell Growth$277,375
R01 · FY2003 · HL
Role of p70 S6 Kinase in Regulating LAM Cell Growth$277,375
R01 · FY2002 · HL